Medindia

X

Boston Scientific Announces Appointment of Timothy Pratt as General Counsel

Tuesday, April 8, 2008 General News J E 4
Advertisement
NATICK, Mass., April 7, 2008 Boston ScientificCorporation (NYSE: BSX) today announced the appointment of Timothy Pratt asits new General Counsel. Pratt is a nationally known attorney specializing inmedical device and pharmaceutical litigation. He will hold the title of"Executive Vice President, Secretary and General Counsel;" he will serve onthe Company's Executive Committee, and he will report to President and ChiefExecutive Officer Jim Tobin. He plans to join the Company May 1st.

Pratt comes to Boston Scientific after 31 years with the Kansas City lawfirm of Shook, Hardy & Bacon, where he has been a partner and co-chair of thefirm's 100-attorney Pharmaceutical and Medical Device Litigation Division. Hehas a broad range of experience representing a variety of medical device andpharmaceutical companies, and he has received numerous recognitions for hisaccomplishments.

Pratt has focused his practice on cardiac devices, including pacemakers,defibrillators and cardiac resynchronization therapy devices. He has servedas lead outside counsel for Guidant Corporation's Cardiac Rhythm Managementbusiness since the early 1990s. Boston Scientific acquired Guidant in 2006.

Prior to joining Shook, Hardy & Bacon, he was a law clerk to Chief JudgeFloyd R. Gibson of the U.S. Court of Appeals for the Eighth Circuit.

Pratt is a graduate of Drake University Law School, where he was Editor inChief of the Law Review.

"As one of the nation's premier medical device attorneys, Tim brings adeep understanding of our industry, as well as long familiarity with ourCompany," said Tobin. "We are fortunate to have someone of his experience andcaliber leading our Legal team and providing strategic advice and counsel onthe increasingly intersecting environment of legal and business issues. Welook forward to welcoming Tim to Boston Scientific."

Pratt replaces Paul Sandman, who retired as General Counsel in Februaryafter 14 years with the Company.

Boston Scientific is a worldwide developer, manufacturer and marketer ofmedical devices whose products are used in a broad range of interventionalmedical specialties. For more information, please visit:www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaningof Section 21E of the Securities Exchange Act of 1934. Forward-lookingstatements may be identified by words like "anticipate," "expect," "project,""believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates usinginformation available to us at the time and are not intended to be guaranteesof future events or performance. These forward-looking statements include,among other things, statements regarding clinical trials, scientificactivities, our medical input process, growth investment and educationalpublications. If our underlying assumptions turn out to be incorrect, or ifcertain risks or uncertainties materialize, actual results could varymaterially from the expectations and projections expressed or implied by ourforward-looking statements. These factors, in some cases, have affected andin the future (together with other factors) could affect our ability toimplement our business strategy and may cause actual results to differmaterially from those contemplated by the statements expressed in this pressrelease. As a result, readers are cautioned not to place undue reliance onany of our forward-looking statements.

Factors that may cause such differences include, among other things:future economic, competitive, reimbursement and regulatory conditions; newproduct introductions; demographic trends; intellectual property; litigation;financial market conditions; and, future business decisions made by us and ourcompetitors. All of thes
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Light Sciences Oncology Appoints David P. Holveck ...
S
Haemonetics Sets Date for Fourth Quarter and Fisca...